NIMH

Genome-wide association analyses identify 95 risk loci and provide insights into the neurobiology of post-traumatic stress disorder

Retrieved on: 
Thursday, April 18, 2024
Harvard University, University, Genetics, Post-traumatic stress disorder, Meta-analysis, Fear, Broad Institute, Eurosport 1, Neuroscience, Cognition, PTSD, Chairperson, Trauma, Hand, University of California, Genetic variation, Doctor of Philosophy, Research, URL, Life, Axon guidance, Native, Survivor, Therapy, SURFnet, Mental health, Psychiatric Genomics Consortium, DSM-IV codes, Psychiatric Genetics (journal), Nature Genetics, MIT, Genome, Diagnosis, Biology, NIMH, Synapse, Frequency response, Meat

NEW YORK, April 18, 2024 /PRNewswire/ -- The Global PTSD Genetics initiative founded in 2015 by Cohen Veterans Bioscience, the Stanley Center for Psychiatric Research at Broad Institute, and the Psychiatric Genomics Consortium today announces a pivotal milestone in the genetics of post-traumatic stress disorder (PTSD) has been achieved and published in Nature Genetics on April 18,2024.

Key Points: 
  • Convergent multiomic approaches identified 43 potential causal genes, including modulators of neurotransmitters, ion channels, axon guidance, and synapses.
  • Additional top genes influence stress, immune, fear, and threat-related processes, previously hypothesized to underlie PTSD neurobiology.
  • These findings strengthen the understanding of neurobiological systems relevant to PTSD pathophysiology, while also opening new areas for investigation.
  • Posttraumatic stress disorder (PTSD) is characterized by intrusive thoughts, hyperarousal, avoidance, and negative alterations in cognition and mood that can become persistent for some individuals after traumatic event exposure.

Helping Children and Adolescents with Emotional Problems: Free Webinar for Parents and Educators from the Brain & Behavior Research Foundation

Retrieved on: 
Thursday, November 16, 2023
Adolescence, Self Control (Raf song), Research, Anxiety, NIMH, Student, Mental health, Mood, Emotion, Anxiety disorder, Brain, Parent, Nursing, Child

The Brain & Behavior Research Foundation (BBRF) will host a webinar on Thursday, November 30, at 7pm EDT, via Zoom, to share with parents and educators the key symptoms and attributes associated with pediatric mood and anxiety disorders.

Key Points: 
  • The Brain & Behavior Research Foundation (BBRF) will host a webinar on Thursday, November 30, at 7pm EDT, via Zoom, to share with parents and educators the key symptoms and attributes associated with pediatric mood and anxiety disorders.
  • Families and educators are often the first to recognize that a child is struggling.
  • Pine and Borenstein will discuss novel insights for improving treatment and offer tools to help families and educators address how best to help children and teens with emotional issues.
  • The webinar will also highlight particularly pressing questions in research on pediatric mood and anxiety disorders while outlining an agenda for future research.

Announcing 35th Annual Walk for Hope on Sunday, Oct 8

Retrieved on: 
Wednesday, September 6, 2023
Depression, Argyreia nervosa, National Institute of Mental Health, Schizophrenia, Mental health, NIMH, Research, Triangle, Organization, Embers, Treatment, Mental disorder, Psychiatry, Walking, Memory, Bipolar disorder, PTSD, Nursing, Hope

The 5K annual walk, which raises money for mental illness research, also includes a festival featuring music by the Embers, carnival-style entertainment, prizes, t-shirts, a delicious lunch, and more.

Key Points: 
  • The 5K annual walk, which raises money for mental illness research, also includes a festival featuring music by the Embers, carnival-style entertainment, prizes, t-shirts, a delicious lunch, and more.
  • Those who cannot join in person can walk or run virtually at their leisure or donate to support mental illness research here in our community.
  • Today, the Walk has become a Triangle family tradition and one of the nation's largest and oldest walk fundraisers benefiting mental illness research.
  • The Foundation of Hope for Research and Treatment of Mental Illness is a 501(c)(3) nonprofit organization based in Raleigh, North Carolina.

MATT STEVENSON JUNIOR TENNIS TOURNAMENT (NY) EXPANDS ITS MENTAL HEALTH MISSION AT FLUSHING MEADOWS

Retrieved on: 
Tuesday, September 5, 2023
Tennis, Depression, American Foundation for Suicide Prevention, ProtoStar, Suicide, USTA, National Institute of Mental Health, ATP Challenger Tour, Tournament, Parent, Anxiety, AFSP, National Suicide Prevention Week, Mental health, NIMH, Youth Mental Health Protection Act, Code, Eastern Sectional Figure Skating Championships, Mental, CDC, Doubles, Organization, School, Report, Matt, Singles, SAN, Love, Grammatical mood, Stage fright, Suicidal ideation, United States Tennis Association, Nursing, Sports equipment, Flushing Meadows–Corona Park

SAN DIEGO, Sept. 5, 2023 /PRNewswire/ -- The Matt Stevenson Junior Tennis Tournament (NY), which will again take place at Flushing Meadows, NY, right after the U.S. Open, is expanding its Mental Health mission to include "The Team Approach." New this year are interactive exercises for parents/guardians on supporting the emotional well-being of their junior tennis players.

Key Points: 
  • SAN DIEGO, Sept. 5, 2023 /PRNewswire/ -- The Matt Stevenson Junior Tennis Tournament (NY), which will again take place at Flushing Meadows, NY, right after the U.S. Open, is expanding its Mental Health mission to include "The Team Approach."
  • Matt Stevenson Junior Tennis Tournament returns to NY after U.S. Open with new mental health resources for parents!
  • This Tournament is unique in that it is the first and only junior tennis tournament in the country to promote the importance of Youth Mental Health as part of the event.
  • In 2022, the Tournament added Sport Psychology materials to help junior players understand the interconnection between mental performance on the tennis court and mental health off the tennis court.

PsychoGenics and Collaborations Pharmaceuticals awarded a $1M grant to use AI platforms to design new drugs for mental health disorders

Retrieved on: 
Tuesday, September 5, 2023
Technology, Pharmaceutical, Health, Artificial Intelligence, CPI, Mental disorder, Suicide, National Institute of Mental Health, Schizophrenia, SAR, SBIR, Statistics, Mental health, ML, DSM-IV codes, NIMH, CNS, Disorder, Bangladesh Technical Education Board, Chemistry, Patient, Machine learning, Psychology, Drug discovery, Service, Death, NIH, Bipolar disorder, Pharmacology, Pharmaceutical industry

PsychoGenics Inc. (PsychoGenics) and Collaborations Pharmaceuticals, Inc. (CPI) are pleased to announce that they were awarded a $1million Phase I Small Business Innovation Research (SBIR) grant, to use their combined AI tools to design new drugs for mental health disorders.

Key Points: 
  • PsychoGenics Inc. (PsychoGenics) and Collaborations Pharmaceuticals, Inc. (CPI) are pleased to announce that they were awarded a $1million Phase I Small Business Innovation Research (SBIR) grant, to use their combined AI tools to design new drugs for mental health disorders.
  • Statistics reveal that approximately one in four individuals experiences a mental disorder at some point in their lifetime.
  • These disorders encompass a wide spectrum, including major depressive disorder, bipolar disorder, schizophrenia, and substance use disorders, impacting people of all age groups.
  • Our AI tools, combined with PsychoGenics’ Cube platforms and collective experience, render the ambitious goal of discovering new classes of drugs feasible."

E-bike battery market to grow by USD 2.11 billion from 2022 to 2027 | The longer shelf life of Li-ion batteries to drive growth - Technavio

Retrieved on: 
Wednesday, August 23, 2023
Giant, Lithium, Urbanization, Johnson Matthey, VARTA, Aviation, NIMH, LG Corporation, Lithium iron phosphate battery, USD, Comprehensive, Giant Bicycles, Investment, Developed country, Municipal solid waste, Growth, Transport, Rest, Geography, Electric battery

Therefore, these factors and rapid growth will boost the growth of the market in this region during the forecast period.

Key Points: 
  • Therefore, these factors and rapid growth will boost the growth of the market in this region during the forecast period.
  • Buy Now
    The longer shelf life of Li-ion batteries when compared with other battery technologies is the key driver for the growth of the e-bike battery market.
  • The flow battery market size is estimated to grow at a CAGR of 22.16% between 2022 and 2027.
  • The lithium-sulfur battery market size is estimated to grow at a CAGR of 33.06% between 2022 and 2027.

iRxReminder Announces Enrollment of Initial Patients in Groundbreaking Tardive Dyskinesia Detection Study

Retrieved on: 
Wednesday, August 2, 2023
Internet of things, DSM-IV codes, OH, Fermata, Health, NIMH, Patient, Patient safety, Machine learning, FDA, Mental health, Tardive dyskinesia, Medical device

The primary objective of this groundbreaking study is to validate automated identification of Tardive Dyskinesia, a potentially life-threatening adverse event associated with certain medications used by mental health patients.

Key Points: 
  • The primary objective of this groundbreaking study is to validate automated identification of Tardive Dyskinesia, a potentially life-threatening adverse event associated with certain medications used by mental health patients.
  • iRxReminder, LLC announces the enrollment of patients NIMH-funded study, the TDtect Diagnostic.™ for Tardive Dyskinesia
    Owen Muir, M.D.
  • , Chief Medical Officer at iRxReminder, expressed, "This study represents a significant stride in our commitment to enhancing patient safety and outcomes.
  • For more information about iRxReminder, the TDetect study, or any related initiatives, please contact Larry Tusick at 440.668.2966, [email protected]

Arcade Therapeutics and UT Austin Jointly Announce a $3.8M NIMH Grant to Fund Large Clinical Trial Testing the Efficacy of ABM-02, The First Game-Based Digital Therapeutic for Major Depressive Disorder

Retrieved on: 
Wednesday, July 26, 2023
Arcade, Depression, University, R01, Clinical trial, Mental Health Research Institute (Melbourne), Mental health, DSM-IV codes, NIMH, National Institute of Mental Health, Trial of the century, ABM, MDD, 1996-10-24 Frank Erwin Center, University of Texas, Austin, TX, Patient, University of Texas at Austin, Entrepreneurship, Principal, FDA, Therapy, News, National Institute for Health and Care Excellence, Pharmaceutical industry, Psychology, Center for Transportation Research UT Austin

NEW YORK, July 26, 2023 /PRNewswire/ -- Arcade Therapeutics, a leading developer of game-based therapies for mental health, and University of Texas Austin's Institute for Mental Health Research, a leading research center in the field of depression, jointly announced the closing of a $3.8M grant from the National Institute for Mental Health (NIMH) to support clinical investigation and validation of ABM-02 as a game-based treatment for Major Depressive Disorder (MDD).

Key Points: 
  • The study will assess 600 participants suffering from depression across these three, randomly-assigned arms, and will be the largest and most rigorous test of ABM for depression ever completed.
  • Arcade intends to use findings from this ambitious clinical study to support their FDA submission of ABM-02 as the first game-based treatment for Major Depressive Disorder.
  • This news follows the recent success of a clinical trial investigating Arcade's flagship therapeutic game, StarStarter Rx (aka ABM-01) as the first game-based treatment for the most prevalent anxiety condition, Social Anxiety Disorder.
  • Co-Founder and Chief Science Officer of Arcade Therapeutics, Tracy Dennis-Tiwary PhD added, "Only half of those suffering from depression seek and receive treatment.

EPI’s Pulvinar Neuro is Awarded $3 Million NIH Grant for Transcranial Stimulation Research

Retrieved on: 
Tuesday, May 16, 2023
Science, Neurology, Research, Health, Mental Health, Medical Devices, Health Technology, Clinical Trials, EPI, Mental health, NIMH, Multimedia, Phase II, Bangladesh Technical Education Board, TCS, DSM-IV codes, Patient, Pulvinar, NIH, Pharmaceutical industry

Pulvinar Neuro , a wholly owned subsidiary of Electromedical Products International, Inc. (EPI) developing non-invasive brain stimulation devices, was awarded a grant from the National Institutes of Health (NIH) to further its research in transcranial stimulation (TCS) as a potential treatment for psychiatric disorders.

Key Points: 
  • Pulvinar Neuro , a wholly owned subsidiary of Electromedical Products International, Inc. (EPI) developing non-invasive brain stimulation devices, was awarded a grant from the National Institutes of Health (NIH) to further its research in transcranial stimulation (TCS) as a potential treatment for psychiatric disorders.
  • The grant also includes funding for a double-blind, placebo-controlled study of the cloud-enabled TCS device in 30 patients with major depressive disorder.
  • "This NIH grant will enable us to take a key step forward in the development of our novel brain stimulation treatment for mental illness," said Leah Townsend, Ph.D., chief science officer, EPI.
  • Research reported in this press release was supported by the National Institute of Mental Health of the National Institutes of Health under award number R44MH119872.

Click Therapeutics and Boehringer Ingelheim Initiate Pivotal Clinical Trial of Prescription Digital Therapeutics for the Treatment of Negative Symptoms in Schizophrenia

Retrieved on: 
Thursday, May 4, 2023
Software, Biotechnology, Pharmaceutical, General Health, Health, FDA, Technology, Clinical Trials, Consensus, Consensus decision-making, Hallucination, Partnership, Therapy, Motivation, Disability, Perception, Clinical trial, Psychopharmacology, Mental health, DSM-IV codes, NIMH, Doctor of Philosophy, CNS, Boehringer Ingelheim, MD, Patient, Risk, Diagnosis, Digital, National Institute of Mental Health, FAAN, Behavior, Disease, Pharmaceutical industry, Nursing, Schizophrenia

Click Therapeutics, Inc. (“Click”), a leader in Digital Therapeutics™ as prescription medical treatments, today announced the initiation of the CONVOKE Study , a registrational clinical trial to investigate the use of prescription digital therapeutics as an adjunct treatment to standard of care antipsychotic therapy to treat the negative symptoms of schizophrenia in patients 18 years and older.

Key Points: 
  • Click Therapeutics, Inc. (“Click”), a leader in Digital Therapeutics™ as prescription medical treatments, today announced the initiation of the CONVOKE Study , a registrational clinical trial to investigate the use of prescription digital therapeutics as an adjunct treatment to standard of care antipsychotic therapy to treat the negative symptoms of schizophrenia in patients 18 years and older.
  • The study intervention period will be 16 weeks and efficacy will be assessed by the Clinical Assessment Interview for Negative Symptoms, Motivation and Pleasure scale (CAINS-MAP).
  • The CAINS-MAP measures experiential negative symptoms, the clinical target of interest in the evaluation of efficacy in this study.
  • “Our partnership with Click Therapeutics, who share a like-minded goal through our approach to prescription digital therapeutics, has the potential to address significant unmet needs in schizophrenia.